Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
8.13
+0.17 (2.14%)
At close: Aug 5, 2025, 4:00 PM
8.13
0.00 (0.00%)
After-hours: Aug 5, 2025, 4:55 PM EDT
Amneal Pharmaceuticals Employees
Amneal Pharmaceuticals had 8,300 employees as of December 31, 2024. The number of employees increased by 450 or 5.73% compared to the previous year.
Employees
8,300
Change (1Y)
450
Growth (1Y)
5.73%
Revenue / Employee
$343,725
Profits / Employee
$407
Market Cap
2.55B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8,300 | 450 | 5.73% |
Dec 31, 2023 | 7,850 | 250 | 3.29% |
Dec 31, 2022 | 7,600 | 600 | 8.57% |
Dec 31, 2021 | 7,000 | 1,000 | 16.67% |
Dec 31, 2020 | 6,000 | 500 | 9.09% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AMRX News
- 4 hours ago - Amneal Pharmaceuticals, Inc. (AMRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 11 hours ago - Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico - GlobeNewsWire
- 13 hours ago - Amneal Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 15 days ago - Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032 - GlobeNewsWire
- 15 days ago - Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results - GlobeNewsWire
- 18 days ago - Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada - GlobeNewsWire
- 27 days ago - Amneal to Report Second Quarter 2025 Results on August 5, 2025 - GlobeNewsWire
- 5 weeks ago - Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences - GlobeNewsWire